Reviewing Hypera (OTCMKTS:HYPMY) and Myovant Sciences (NYSE:MYOV)
Reviewing Hypera (OTCMKTS:HYPMY) and Myovant Sciences (NYSE:MYOV)
Hypera (OTCMKTS:HYPMY – Get Rating) and Myovant Sciences (NYSE:MYOV – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Hypera(OTCMKTS：HYPMY-GET Rating)和Myovant Sciences(NYSE：MYOV-GET Rating)都是醫療公司，但哪一家業務更好？我們將根據兩家公司的分析師推薦、風險、機構持股、估值、股息、收益和盈利能力的強弱對它們進行比較。
Risk and Volatility
風險和波動性
Hypera has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
Hypera的貝塔係數為0.8，表明其股價的波動性比標準普爾500指數低20%。相比之下，Myovant Sciences的貝塔係數為2.28，這表明其股價的波動性比標準普爾500指數高128%。
Profitability
盈利能力
This table compares Hypera and Myovant Sciences' net margins, return on equity and return on assets.
下表比較了Hypera和Myovant Sciences的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Hypera | N/A | N/A | N/A |
| Myovant Sciences | -54.03% | N/A | -29.25% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 金絲桃組 | 不適用 | 不適用 | 不適用 |
| Myovant Science | -54.03% | 不適用 | -29.25% |
Valuation & Earnings
估值與收益
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hypera | $793.81 million | 6.73 | $251.25 million | N/A | N/A |
| Myovant Sciences | $230.97 million | 8.23 | -$205.98 million | ($1.76) | -11.26 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 金絲桃組 | 7.9381億美元 | 6.73 | 2.5125億美元 | 不適用 | 不適用 |
| Myovant Science | 2.3097億美元 | 8.23 | -2.0598億美元 | ($1.76) | -11.26 |
Hypera has higher revenue and earnings than Myovant Sciences.
Hypera的收入和收益都高於Myovant Sciences。
Insider and Institutional Ownership
內部人與機構持股
0.1% of Hypera shares are owned by institutional investors. Comparatively, 30.6% of Myovant Sciences shares are owned by institutional investors. 1.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Hypera 0.1%的股份由機構投資者持有。相比之下，Myovant Sciences 30.6%的股份由機構投資者持有。Myovant Sciences 1.9%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一隻股票有望實現長期增長。
Analyst Recommendations
分析師建議
This is a summary of recent ratings and target prices for Hypera and Myovant Sciences, as reported by MarketBeat.
據MarketBeat報道，這是Hypera和Myovant Sciences最近的評級和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hypera | 0 | 0 | 0 | 0 | N/A |
| Myovant Sciences | 0 | 1 | 1 | 0 | 2.50 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 金絲桃組 | 0 | 0 | 0 | 0 | 不適用 |
| Myovant Science | 0 | 1 | 1 | 0 | 2.50 |
Myovant Sciences has a consensus target price of $17.67, suggesting a potential downside of 10.86%. Given Myovant Sciences' higher possible upside, analysts clearly believe Myovant Sciences is more favorable than Hypera.
Myovant Sciences的一致目標價為17.67美元，這意味着潛在的下跌幅度為10.86%。考慮到Myovant Sciences更有可能的上行空間，分析師們顯然認為Myovant Sciences比Hypera更有利。
Summary
摘要
Myovant Sciences beats Hypera on 6 of the 11 factors compared between the two stocks.
Myovant Sciences在兩隻股票的11個指標中有6個擊敗了Hypera。
About Hypera
關於Hypera
(Get Rating)
(獲取評級)
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Hypera S.A.在巴西是一家制藥公司。它提供的處方藥有Adacne、Addera、Apri、AmpliumG、請、賽萊他明、Celstone、Celstone Soluspana、Cizax、DECPRAX、衍生CMicro、Micro Drift、Dermol Fusid、Digedrat、雙丙胺、雙丙沙星、雙丙鬆、雙丙鬆、Emprol XR、Flow、Garasone、Halobx、Lipanon、Moon、Lydian、Macrodantin、MaxSulid、MilGamma、Mioflex-A、Nesina、Novotram、oximax、peridid、Perida混懸劑、Predsim、Pressaliv、Quadriderm、Rizi、Rizi、Softalm、acrotz、tinodin、umma和velunid品牌。該公司還提供Mantecorp護膚品品牌的皮膚化粧品，以及Aprur、Benegrip、Coristina d、Engov、Epocler、Estomazil等品牌的消費者保健產品。此外，該公司還提供Tamarine、Vitasay、BiotôNico Fonoura和Zero-Cal品牌的營養和維生素補充劑產品；以及Neo quí雲母、雙氯芬酸鈉、羥基肼、地比隆、布洛芬、氯沙坦鉀、MAL地塞米拉明、奈普生、撲熱息痛、西美康、氯雷他定、奧美拉唑、他達和地格列酮品牌下的類似和仿製藥。該公司前身為Hypermarcas S.A.，並於2018年2月更名為Hypera S.A.。Hypera S.A.總部設在巴西的São Paulo。
About Myovant Sciences
關於Myovant Science
(Get Rating)
(獲取評級)
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Myovant Sciences Ltd.是一家生物製藥公司，為女性和男性開發重新定義的護理。該公司的主導產品是relugolix，這是一種每天口服一次的小分子藥物，用作促性腺激素釋放激素受體拮抗劑，用於治療與子宮肌瘤、子宮內膜異位症相關疼痛和晚期前列腺癌相關的月經大出血。它還在開發MVT-602，一種寡肽Kispeptin激動劑，作為輔助生殖的一部分，正在進行治療女性不孕不育的第二階段臨牀試驗。Myovant Science Ltd.與輝瑞公司合作，開發和商業化治療腫瘤學和婦女健康的瑞盧格利克斯。該公司前身為Roivant Endocinology Ltd.，並於2016年5月更名為Myovant Sciences Ltd.。該公司成立於2016年，總部設在英國倫敦。Myovant Science Ltd是Sumitovant Biophma Ltd.的子公司。
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
接受Hypera Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Hypera和相關公司的最新新聞和分析師評級的每日簡要摘要。